BioSpace News Archive

Drug Development

Mirati’s KRAS Inhibitor Promising in Early-Stage Trial of Solid Tumors

San Diego-based Mirati Therapeutics announced the first clinical data from its Phase I/II clinical trial of MRTX849 in solid tumors. MRTX849 is a KRAS G12C inhibitor.

October 29, 2019
·
2 min read
·
Mark Terry
Policy

PixarBio CEO Who Claimed He Cured Paralysis Convicted of Defrauding Investors

Reynolds claimed that his company’s product, called NeuroRelease, could essentially end paralysis.

October 29, 2019
·
2 min read
·
Alex Keown
Business

Disc Medicine Closes $50 Million Series A and Inks Licensing Deal with AbbVie

Disc Medicine is focused on hepcidin biology to restore red blood cell production in hematologic diseases.

October 29, 2019
·
3 min read
·
Mark Terry
Bio NC

Your Feedback Matters! Biopharma Company Culture

As a valued member of our BioSpace community, we are eager to hear more from you and other readers as we head towards the end 2019. We want to know if your company has a positive culture.

October 29, 2019
·
1 min read
·
BioSpace Staff
Pharm Country

WCG Clinical Research Thought Leaders to Present at MAGI West

Topics to be covered include IRB outsourcing, human subject protections and data privacy, patient-centric clinical trials, and the evolving clinical site landscape

October 29, 2019
·
2 min read
MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility

MorphoSys AG announced the end of the clinical development program of MOR106 in atopic dermatitis.

October 29, 2019
·
4 min read
Global BioLife Inc. to present Functional Fragrance Formula at the American Society for Microbiology’s Biothreats Conference as a New Method to Prevent and Treat Tuberculosis

SGX-listed Singapore eDevelopment Limited wishes to announce that its biomedical subsidiary incorporated in Nevada, Global BioLife Inc. will be presenting its research on its Functional Fragrance Formula against tuberculosis at the 2020 American Society for Microbiology Biothreats Conference.

October 29, 2019
·
4 min read
Deals

BioVersys Receives CARB-X Award of up to US$ 8.92 Million for Development of Novel Antimicrobial Therapies

BioVersys AG announced, US$ 3.94 million in non-dilutive funding from CARB-X, with the possibility of US$ 4.98 million more if certain project milestones are met.

October 29, 2019
·
5 min read
Owlstone Medical to Contribute Breath Biopsy to 3TR, the Largest-ever IMI2 Immunology Project to Improve Disease Management Across Seven Immune-Mediated Diseases

Large-scale public-private research initiative designed to provide new insights into the mechanisms of response and non-response to treatment within and across seven different immune-mediated diseases

October 29, 2019
·
8 min read
Drug Development

After Futility Analysis, MorphoSys, Galapagos and Novartis Halt Dermatitis Program

The companies indicate that the decision was based on lack of efficacy, not any safety concerns.

October 29, 2019
·
2 min read
·
Mark Terry